drugset / Trial / NCT04003818
Efficacy and Safety of Teicoplanin in CDAD
NaSingle-groupOpen-labelTreatment
Summary
Primary Objective: Explore the efficacy of teicoplanin (100-200 mg administered orally twice a day for 7 to 14 days) in patients with Clostridium difficile infection-associated diarrhea and colitis Secondary Objective: Evaluate the safety of teicoplanin in patients with Clostridium difficile infection-associated diarrhea and colitis
Timeline
- Start
- 2020-05-15
- Primary completion
- 2021-01-21
- Completion
- 2021-03-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teicoplanin | Other / unclassified | 100 mg | Oral |
| Subject | Teicoplanin | Other / unclassified | 200 mg | Oral |